Page 7 of 12
ACS Medicinal Chemistry Letters
cose and Lipid-Lowering Activities. J. Med. Chem. 2005, 48,
ticoid Receptor (GR); Pregnane X Receptor (PXR); Retinoid
1
2
3
4
5
6
7
8
2248-2250.
X Receptor RXR.
13. Li, J.; Kennedy, L. J.; Shi, Y.; Tao, S.; Ye, X.-Y.; Chen, S. Y.;
Wang, Y.; Hernández, A. S.; Wang, W.; Devasthale, P. V.;
Chen, S.; Lai, Z.; Zhang, H.; Wu, S.; Smirk, R. A.; Bolton, S.
A.; Ryono, D. E.; Zhang, H.; Lim, N.-K.; Chen, B.-C.; Locke,
K. T.; O’Malley, K. M.; Zhang, L.; Srivastava, R. A.; Miao, B.;
Meyers, D. S.; Monshizadegan, H.; Search, D.; Grimm, D.;
Zhang, R.; Harrity, T.; Kunselman, L. K.; Cap, M.; Kadiyala,
P.; Hosagrahara, V.; Zhang, L.; Xu, C.; Li, Y.-X.; Muckelbau-
er, J. K.; Chang, C.; An, Y.; Krystek, S. R.; Blanar, M. A.; Zah-
ler, R.; Mukherjee, R.; Cheng, P. T. W.; Tino, J. A. Discovery
of an Oxybenzylglycine Based Peroxisome Proliferator Acti-
REFERENCES
1.
Pirat, C.; Farce, A.; Lebègue, N.; Renault, N.; Furman, C.;
Millet, R.; Yous, S.; Speca, S.; Berthelot, P.; Desreumaux, P.;
Chavatte, P. Targeting peroxisome proliferator-activated re-
ceptors (PPARs): development of modulators. J. Med. Chem.
2012, 55, 4027-4061.
2. Cheng, P. T. W.; Mukherjee, R. PPARs as targets for meta-
bolic and cardio-vascular diseases. Mini-Rev. Med. Chem.
2005, 5, 741-753.
3. Staels, B.; Dallongeville, J.; Auwerx; J.; Schoonjans, E.; Lei-
tersdorf, E.; Fruchart, J.-C. Mechanism of action of fibrates
on lipid and lipoprotein metabolism. Circulations, 1998, 98,
2088-2093.
4. Saurav, A.; Kaushik, M.; Mohiuddin, S. M. Fenofibric acid
for hyperlipidemia. Exp. Opin. Pharmacother. 2012, 13, 717-
722.
5. Todd, P. A.; Ward, A. Gemfibrozil. A review of its pharma-
codynamic and pharmacokinetic properties, and therapeu-
tic use in dyslipidaemia. Drugs 1988, 36, 314-339.
6. Dietz, M.; Mohr, P.; Kuhn, B.; Maerki, H. P.; Hartman, P.;
Ruf, A.; Benz, J.; Grether, U.; Wright, M. B. Comparative
molecular profiling of the PPARα/γ activator aleglitazar:
PPAR selectivity, activity and interaction with cofactors.
ChemMedChem. 2012, 7, 1101-1011.
7. Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic drugs,
polyunsaturated fatty acids, and eicosanoids are ligands for
peroxisome proliferator-activated receptors alpha and delta.
Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4312-4317.
8. Sierra, M. L.; Beneton, V.; Boullay, A-B.; Boyer, T.; Brewster,
A. G.; Donche, F.; Forest, M-C.; Fouchet, M-H.; Gellibert, F.
J.; Grillot, D. A.; Lambert, M. H.; Laroze, A.; Le Grumelec,
C.; Linget, J. M.; Montana, V. G.; Nguyen, V-L.; Nicodeme,
E.; Patel, V.; Penfornis, A.; Pineau, O.; Pohin, D.; Potvain, F.;
Poulain, G.; Ruault, C. B.; Saunders, M.; Toum, J.; Xu, H. Er-
ic; Xu, R. X.; Pianetti, P. M. Substituted 2-[(4-
aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha
agonists. 1. Discovery of a novel series of potent HDLc rais-
ing agents. J. Med. Chem. 2007, 50, 685-695.
9. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.;
Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.;
Bensch, W. R.; Barr, R. W.; Osborne, J.; Montrose-
Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-
Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B. Design and
Synthesis of a Potent and Selective Triazolone-Based Perox-
isome Proliferator-Activated Receptor α Agonist. J. Med.
Chem. 2003, 46, 5121-5124.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
vated Receptor
Chlorophenyl)-5-methyloxazol-4-
yl)methoxy)benzyl)(methoxycarbonyl)-amino)acetic Acid
(BMS-687453). J. Med. Chem. 2010, 53, 2854–2864.
α
Selective Agonist 2-((3-((2-(4-
14. Ye, X.-Y.; Chen, S. Y.; Zhang, H.; Locke, K. T.; O’Malley, K.;
Zhang, L.; Srivastava, R. A.; Miao, B.; Meyers, D. S.; Mon-
shizadegan, H.; Search, D.; Grimm, D.; Zhang, R.; Lippy, S.
J.; Twamley, C.; Muckelbauer, J. K.; Chang, C.; An, Y.;
Hosagrahara, V.; Zhang, L.; Yang, T-J., Mukherjee, R.;
Cheng, P. T. W.; Tino, J. Synthesis and structure–activity re-
lationships of 2-aryl-4-oxazolylmethoxybenzylglycines and
2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent
PPARα selective activators- PPARα and PPARγ selectivity
modulation. Bioorg. Med. Chem. Lett. 2010, 20, 2933-2937.
15. Zhang, H.; Yan, P. F.; Zhang, G-L. Preparation of 2-(1-
Chloroalkyl)-4,5-dimethyloxazoles and (E)-2-Alkenyl-4,5-
dimethyloxazoles. Synthesis 2006, 11, 1763-1766.
16. Seethala, R.; Golla, R.; Ma, Z.; Zhang, H.; O'Malley, K.; Lip-
py, J.; Cheng, L.; Mookhtiar, K.; Farrelly, D.; Zhang, L.; Ha-
riharan, N.; and Cheng. P. T. A rapid, homogeneous, fluo-
rescence polarization binding assay for peroxisome prolifer-
ator-activated receptors alpha and gamma using a fluores-
cein-tagged dual PPARalpha/gamma activator. Anal. Bio-
chem. 2007, 363, 263-274.
17. Compound 2 shows full PPARα agonist activity in rodents
with EC50s of 488 nM, 426 nM and 317 nM for hamster,
mouse and rat, respectively.
18. Compound 3 has following profile: Plasma Protein binding:
99.7% (h), 99.8% (m), 99.6% (r), 99% (c), 99.5% (d); CYP
(inhibition) 3A4, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, all IC50s >
40 ꢀM. PXR EC60 > 50 ꢀM; HHA (2C19, 2C9, 2D6, 3A4, TC5)
all IC50 > 150 ꢀM; hERG (flux) IC50 > 80 ꢀM; (patch-clamp)
4.0% at 30 μM; Sodium Channel (EP, % block @ 10 ꢀM): 12%
@ 1 Hz and 14% @ 4 Hz; Purkinje fiber% change APD90 = -
5.4 @ 30 ꢀM.
19. Mukherjee, R.; Locke, K. T.; Miao, B.; Meyers, D.; Mon-
shizadegan, H.; Zhang, R.; Search, D.; Grimm, D.; Flynn, M.;
O’Malley, K. M.; Zhang, L.; Li, J.; Shi, Y.; Kennedy, L. J.;
Blanar, M.; Cheng, P. T.; Tino, J. A.; Srivastava, R. A. Novel
10. Sosale, A.; Saboo, B.; Sosale B. Diabetes Metab Syndr Obes.
2015, 8, 189-196.
11. Pawlak, M.; Lefebvre, P.; Staels, B. Molecular mechanism of
PPARα action and its impact on lipid metabolism, inflam-
mation and fibrosis in non-alcoholic fatty liver disease. J.
Hepatol. 2015, 62, 720-733.
12. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang,
W.; Zhang, H.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.;
Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.;
Sun, W.; Tieman, A.; Wetterau, J. R..; Doweyko, A.; Chan-
drasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V.
G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.;
Cheng, P. T. W. Design and Synthesis of N-[(4-
Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-
Peroxisome Proliferator-Activated Receptor
α Agonists
Lower Low-Density Lipoprotein and Triglycerides, Raise
High-Density Lipoprotein, and Synergistically Increase
Cholesterol Excretion with a Liver X Receptor Agonist. J.
Pharmacol. Exp. Ther. 2008, 327, 716-726.
20. Berthou, L.; Duverger, N.; Emmanuel., F.; Langouët, S.;
Auwerx, J.; Guillouzo, A.; Fruchart, J. C.; Rubin, E.; Denèfle,
P.; Staels, B.; Branellec, D. Opposite Regulation of Human
Versus Mouse Apolipoprotein A-I by Fibrates in Human
Apolipoprotein A-I Transgenic Mice. J. Clin. Invest. 1996, 97,
2408-2416.
21. Wang, P.R.; Guo, Q.; Ippolito, M.; Wu, M.; Milot, D.; Ven-
tre, J.; Doebber, T.; Wright, S. D.; Chao, Y. S. High fat fed
hamster, a unique animal model for treatment of diabetic
4-oxazolyl)ethoxy]phenyl]methyl]glycine
raglitazar/BMS-298585], a Novel Peroxisome Proliferator-
[Mu-
Activated Receptor α/γ Dual Agonist with Efficacious Glu-
ACS Paragon Plus Environment